VolitionRX Stock News

VolitionRx Limited (NYSE:VNRX ) Q2 2025 Earnings Conference Call August 15, 2025 8:30 AM ET Company Participants Andrew Retter - Chief Medical Officer Cameron Reynolds - Founder, CEO, President & Director Louise Batchelor Day - Group Chief Marketing & Communications Officer Terig Hughes - CFO & Treasurer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Div...

Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

HENDERSON, Nev. , Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i)  156,250 shares of its common stock to certain directors and executive officers of the Company (collectively, the "Insiders") at an offering pri...

HENDERSON, Nev., July 16, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides an update on the significant commercial and scientific progress of its Nu.Q® Discover program.

HENDERSON, Nev. , July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device.

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev. , June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit...

HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentat...